8-K: Biora Therapeutics Faces Nasdaq Delisting After Failing to Meet Market Value Requirement

Biora Therapeutics has received a delisting notice from Nasdaq after failing to maintain the required market value of listed securities, and plans to appeal the decision.

Summary

• Biora Therapeutics received a notice from Nasdaq on December 11, 2023, stating that its market value of listed securities (MVLS) fell below the $50 million threshold.
• The company was given 180 days, until June 10, 2024, to regain compliance with the MVLS rule.
• Biora did not regain compliance by the deadline and received a delisting notice on June 11, 2024.
• The company plans to request a hearing before the Nasdaq Hearing Panel to appeal the delisting.
• The hearing request will temporarily halt the delisting process.
• Biora will present a plan to demonstrate compliance with listing criteria and request an extension of up to 180 days, potentially until December 9, 2024.
• There is no guarantee that the panel will grant the extension or that Biora will be able to meet the listing requirements.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event (delisting notice) and uncertainty about the company's future on the Nasdaq exchange. While the company is appealing, the risk of delisting is high.

Positives

• Biora is actively appealing the delisting notice by requesting a hearing.
• The hearing request will temporarily halt the delisting process.
• The company has the opportunity to present a plan to regain compliance and request an extension.

Negatives

• Biora failed to meet the Nasdaq's minimum market value requirement of $50 million.
• The company received a delisting notice from Nasdaq.
• There is no guarantee that the Nasdaq Hearing Panel will grant an extension.
• The company's stock is at risk of being delisted.

Risks

• The Nasdaq Hearing Panel may not grant Biora's request for continued listing.
• Biora may not be able to demonstrate compliance with listing requirements within the granted time.
• The company's stock could be delisted from the Nasdaq Global Market.
• The company's actual results could differ materially from forward-looking statements due to various risks and uncertainties.

Future Outlook

The company is seeking an extension to regain compliance with Nasdaq listing rules, but there is no guarantee of success. The company is considering all options to regain compliance.

Management Comments

• The company plans to timely request a hearing before the Panel.
• The company will present its plan to evidence compliance with all applicable listing criteria, including the MVLS Rule, and request an extension of time to do so.
• The company is considering all options available to it to regain compliance with the MVLS Rule.

Industry Context

This delisting notice highlights the challenges faced by smaller biotech companies in maintaining market capitalization and meeting exchange listing requirements. It is not uncommon for companies in this sector to face such issues, especially during periods of market volatility or when clinical trial results are not as expected.

Comparison to Industry Standards

• Many small-cap biotech companies face challenges in maintaining the minimum market capitalization required for listing on major exchanges like Nasdaq.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced similar delisting risks due to low market capitalization.
• The Nasdaq's minimum market value requirement is a common hurdle for early-stage biotech firms, and failure to meet this threshold can lead to delisting.

Stakeholder Impact

• Shareholders face the risk of their investment being delisted from the Nasdaq.
• The company's employees may experience uncertainty about the company's future.
• The company's ability to raise capital may be impacted by the delisting notice.

Next Steps

• Biora will request a hearing before the Nasdaq Hearing Panel.
• The company will present a plan to regain compliance with listing requirements.
• Biora will seek an extension of up to 180 days to meet the MVLS rule.

Key Dates

Keywords

delisting, Nasdaq, market value, compliance, hearing, MVLS, Biora Therapeutics, listing rules